文献速递泌尿系感染前列腺增生与排尿功能障碍

新冠疫苗接种后泌尿系统副作用报告率低:VAERS数据分析

Low Rates of Urologic Side Effects Following Coronavirus Disease Vaccination: An Analysis of the Food and Drug Administration Vaccine Adverse Event Reporting System.
PubMed 文献 · Urology · 2021-04-20

该研究检索FDA疫苗不良事件报告系统(VAERS)截至2021年2月12日辉瑞-BioNTech和Moderna新冠疫苗的全部报告,共15,785份不良事件报告中仅0.7%(113份)描述泌尿系统症状,共156条泌尿症状。结论认为接种后泌尿系统症状极为罕见,未显示疫苗与泌尿症状存在相关性,但需继续监测。

要点

  • 15,785份报告中仅0.7%(113份)涉及泌尿系统症状,总体极为罕见。
  • 泌尿症状以尿路感染(26%)、下尿路症状(22%)和其他(28%)为主。
  • 报告者中位年龄63岁,54%为女性,需随接种人群扩大继续监测VAERS。

核心结论

  • 新冠疫苗接种后报告的泌尿系统症状极为罕见,鉴于这些症状在普通人群中常见,目前未显示接种与泌尿症状存在相关性。
  • 随着疫苗接种标准扩大,仍需进一步监测疫苗不良事件报告系统。

研究设计与样本

  • 研究检索FDA疫苗不良事件报告系统(VAERS)截至2021年2月12日辉瑞-BioNTech和Moderna新冠疫苗的全部报告。
  • 共纳入15,785份不良事件报告,分离出全部泌尿系统症状并回顾相关不良事件。

主要发现

  • 15,785份报告中0.7%(113份)描述泌尿系统症状,共记录156条泌尿症状。
  • 辉瑞-BioNTech疫苗占这些报告的61%,Moderna疫苗占39%。
  • 症状分为五类:下尿路症状34条(22%)、血尿22条(14%)、尿路感染41条(26%)、皮肤和/或软组织16条(10%)、其他43条(28%)。
  • 报告泌尿症状患者的中位年龄为63岁(IQR 44-79,范围19-96),54%为女性。

临床怎么用

  • 向患者说明接种新冠疫苗后泌尿系统不良事件报告率极低(0.7%),有助于缓解相关顾虑。
  • 对接种后出现泌尿症状者可按常规泌尿系统疾病评估处理,无需默认归因于疫苗。

局限性

  • VAERS为被动上报系统,可能存在报告偏倚与漏报,无法确立因果关系。
  • 数据截至2021年2月12日,仅覆盖辉瑞-BioNTech和Moderna两种疫苗的早期接种阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantify and describe urologic adverse events and symptoms after vaccination with the Pfizer-BioNTech and Moderna COVID-19 vaccines. METHODS AND MATERIALS: We queried the FDA Vaccine Adverse Event Reporting System (VAERS) for all reported symptoms following the Pfizer-BioNTech and Moderna vaccines as of February 12th, 2021. All urologic symptoms were isolated and the reported adverse events associated with each symptom were reviewed. RESULTS: Out of 15,785 adverse event reports, only 0.7% (113) described urologic symptoms. A total of 156 urologic symptoms were described amongst the 113 adverse event reports. The Pfizer-BioNTech vaccine was responsible for 61% of these reports and the Moderna vaccine was responsible for 39%. These symptoms were grouped into five different categories: Lower Urinary Tract Symptoms (n = 34, 22%), Hematuria (n = 22, 14%), Urinary Infection (n = 41, 26%), Skin and/or Soft Tissue (n = 16, 10%), and Other (n = 43, 28%). The median age of the patients reporting urologic symptoms was 63 years (IQR 44-79, Range: 19-96) and 54% of the patients were female. CONCLUSION: Urologic symptoms reported after COVID-19 vaccination are extremely rare. Given the common prevalence of many of these reported symptoms in the general population, there does not appear to be a correlation between vaccination and urologic symptoms, but as the vaccination criteria expands, further monitoring of the Vaccine Adverse Event Reporting System is needed.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Zhao H, Souders C, Carmel M, et al. Low Rates of Urologic Side Effects Following Coronavirus Disease Vaccination: An Analysis of the Food and Drug Administration Vaccine Adverse Event Reporting System. Urology. 2021. PMID: 33864857. doi:10.1016/j.urology.2021.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。